Trulieve Cannabis (TRLV) Panoramica del titolo
Trulieve Cannabis Corp. opera come rivenditore di cannabis negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 6/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
TRLV Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Trulieve Cannabis Corp.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$11.60 |
| Massimo di 52 settimane | US$13.28 |
| Minimo di 52 settimane | US$4.62 |
| Beta | 1.76 |
| Variazione di 1 mese | 20.21% |
| Variazione a 3 mesi | 22.75% |
| Variazione di 1 anno | 65.24% |
| Variazione a 3 anni | 82.53% |
| Variazione a 5 anni | -55.96% |
| Variazione dall'IPO | -0.64% |
Notizie e aggiornamenti recenti
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking Alpha
TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential
Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.
Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?Recent updates
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking AlphaTRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential
Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?
TRLV: Federal Rescheduling And Georgia Expansion Will Drive Future Upside
Analysts have adjusted their fair value estimate for Trulieve Cannabis from $17.25 to $15.00, citing updated assumptions on revenue trends, profit margins, and future P/E that align with recent Street research and a new $15 price target. Analyst Commentary Recent Street research on Trulieve Cannabis emphasizes both the potential upside tied to regulatory shifts and the risks that could keep the stock under pressure.TRLV: Georgia Expansion And Schedule III Pathway Will Support Future Upside
Analysts have raised their price target on Trulieve Cannabis to $17.25 from $14.08, citing updated assumptions around profit margin, P/E expectations, and other valuation drivers. What’s in the News for Trulieve Cannabis Trulieve Cannabis marked the expansion of Georgia’s medical cannabis program with a ceremonial first sale at its Marietta dispensary under the new "Putting Georgia's Patients First Act." The act allows flower and vaporization products for patients aged 21 and older and broadens qualifying conditions such as lupus, HIV, and inflammatory bowel disease (source: company announcement).Rescheduling Uncertainty And Texas Execution Risks Will Pressure Results Yet Support Long Term Upside
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a vertically integrated cannabis business focused primarily on medical patients across several U.S. states. What are the underlying business or industry changes driving this perspective?TRLV: NYSE Listing And Buybacks Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Trulieve Cannabis from $21.00 to approximately $19.42, citing updated assumptions about long-term profit margins and a slightly lower future P/E multiple. What’s in the News for Trulieve Cannabis Trulieve Cannabis listed on the New York Stock Exchange under the ticker TRLV, becoming the first U.S. based marijuana company on the NYSE after a federal rescheduling of medical marijuana to Schedule III, according to recent news coverage.Trulieve Cannabis (TRLV) Stock Could Be 51.9% Undervalued After NYSE Listing
Trulieve Cannabis (TRLV) has become the first U.S. marijuana company to trade on the New York Stock Exchange, following the federal reclassification of medical marijuana, which opened the door to its uplisting. See our latest analysis for Trulieve Cannabis. The recent NYSE listing comes after a 34.67% 1 month share price return and a 58.56% 3 month share price return. The 1 year total shareholder return of 193.08% and 3 year total shareholder return of 155.70% contrast with a 5 year total...Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator
Catalysts About Trulieve Cannabis Trulieve Cannabis operates cannabis cultivation, production and retail operations serving primarily medical patients across multiple U.S. states. What are the underlying business or industry changes driving this perspective?Rendimenti per gli azionisti
| TRLV | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | -6.7% | -0.6% | -1.6% |
| 1Y | 65.2% | 45.2% | 12.1% |
Ritorno vs Industria: TRLV ha superato il US Pharmaceuticals che ha restituito 45.2 % nell'ultimo anno.
Rendimento vs Mercato: TRLV ha superato il mercato US che ha restituito 12.1 % nell'ultimo anno.
Volatilità dei prezzi
| TRLV volatility | |
|---|---|
| TRLV Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: TRLV non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di TRLV è diminuita da 16% a 9% nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1940 | 5,000 | Kim Rivers | www.trulieve.com |
Trulieve Cannabis Corp. opera come rivenditore di cannabis negli Stati Uniti. L'azienda coltiva, lavora e produce prodotti a base di cannabis e li distribuisce ai propri dispensari, oltre che tramite consegna a domicilio. Vende fiori, prodotti commestibili, vaporizzatori, prodotti per uso orale, topici, concentrati e accessori con i marchi Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors e Roll One.
Trulieve Cannabis Corp. Riepilogo dei fondamenti
| TRLV statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$2.24b |
| Utili (TTM) | -US$467.83m |
| Ricavi(TTM) | US$1.14b |
TRLV è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| TRLV Conto economico (TTM) | |
|---|---|
| Ricavi | US$1.14b |
| Costo del fatturato | US$461.65m |
| Profitto lordo | US$677.39m |
| Altre spese | US$1.15b |
| Utili | -US$467.83m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -2.43 |
| Margine lordo | 59.47% |
| Margine di profitto netto | -41.07% |
| Rapporto debito/patrimonio netto | 37.9% |
Come si è comportato TRLV nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/15 04:55 |
| Prezzo dell'azione a fine giornata | 2026/09/15 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Trulieve Cannabis Corp. è coperta da 16 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Matt Bottomley | Canaccord Genuity |